ODM-108 / Orion Corp - LARVOL DELTA

Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015-2019). (PubMed, Expert Opin Ther Pat) - "During this period, three new molecules entered the clinic (ODM-108, HX-100, and GDC-0334) bringing the total number of TRPA1 antagonists to reach clinical trials to five (including two earlier molecules, CB-625 and GRC 17536); however, to our knowledge, development of all five molecules have been discontinued. Further clinical trials of recent TRPA1 antagonists with good pharmacokinetics would be needed to help understand TRPA1 involvement in human diseases and its potential as a therapeutic target."

Journal • Asthma • Pain • Respiratory Diseases